Zweegman, S., Stege, C. A., Haukas, E., Schjesvold, F. H., Levin, M., Waage, A., . . . Abildgaard, N. (2020). Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. Haematologica.
Citación estilo ChicagoZweegman, Sonja, et al. "Ixazomib-thalidomide-low Dose Dexamethasone Induction Followed By Maintenance Therapy With Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Results From the Randomized Phase II HOVON-126/NMSG 21.13 Trial." Haematologica 2020.
Cita MLAZweegman, Sonja, et al. "Ixazomib-thalidomide-low Dose Dexamethasone Induction Followed By Maintenance Therapy With Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Results From the Randomized Phase II HOVON-126/NMSG 21.13 Trial." Haematologica 2020.